Staodyn
This article was originally published in The Gray Sheet
Executive Summary
Firm's board of directors approves the repurchase of up to 200,000 shares of common "as a result of what the company views as the depressed market price of its common stock," the electromedical treatment devices manufacturer announces. The board also extends to Feb. 28, 1995 the expiration date of the firm's currently outstanding warrants issued in June 1991 and expiring June 19, 1994. Two warrants can be used to buy one share of Staodyn common stock at $5 per share; 920,000 of these warrants are outstanding. The firm notes it has begun shipping its Dermapulse wound management system to Canada and expects to begin marketing the electrostimulation device in Europe within six months